Vir Biotechnology general counsel sells 3,750 shares

The EVP, General Counsel and Corporate Secretary's November 2 sale was automatic for RSU tax withholding; both sales were under a Rule 10b5-1 plan adopted May 26, 2026.

Available on EDGAR 11/04/2026 - 02:56 PM EST Accepted by SEC EDGAR 11/04/2026 - 02:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. EVP, General Counsel and Corporate Secretary Vanina de Verneuil reported two sales of common stock: 1,343 shares at $11.334 per share on November 2, 2026, and 2,407 shares at $11.10 per share on November 3, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted May 26, 2026. The November 2 sale was automatic and mandatory to satisfy the issuer's tax-withholding obligations tied to restricted stock unit vesting, and was not discretionary.

Insider Trade Summary 10b5-1

Net Seller: 3,750 shares

Net Sell 2 txns

Insider de Verneuil Vanina

Role EVP, General Counsel, Corp Sec

Sold 3,750 shs ($42K)

Type	Security	Shares	Price	Value
Sale	Common Stock F3	2,407	$11.10	$27K
Sale	Common Stock F1, F2	1,343	$11.334	$15K

Holdings After Transaction: Common Stock — 110,193 shares (Direct)

Footnotes (3)

1. F1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. Includes 961 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.
3. F3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

Key Figures

Shares sold: 1,343 shares Sale price: $11.334 per share Shares sold: 2,407 shares +2 more

5 metrics

Shares sold 1,343 shares November 2, 2026

Sale price $11.334 per share November 2, 2026

Shares sold 2,407 shares November 3, 2026

Sale price $11.10 per share November 3, 2026

Total shares sold 3,750 shares Reported sales

Key Terms

Rule 10b5-1 trading plan, restricted stock units, tax withholding obligations

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy the Issuer's tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VIR shares did Vanina de Verneuil sell, and at what prices?

Vanina de Verneuil reported sales of 1,343 shares at $11.334 per share on November 2, 2026, and 2,407 shares at $11.10 per share on November 3, 2026. The reported total was 3,750 shares sold; both sales were under a Rule 10b5-1 trading plan adopted May 26, 2026.

Why was the November 2 VIR sale made?

The 1,343-share sale on November 2, 2026 was automatic and mandatory under a Rule 10b5-1 arrangement to satisfy the issuer's tax-withholding obligations in connection with restricted stock unit vesting; it did not represent a discretionary trade by Vanina de Verneuil.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Verneuil Vanina

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel, Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		S(1)		1,343	D	$11.334	112,600(2)	D
Common Stock	11/03/2026		S(3)		2,407	D	$11.1	110,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

2. Includes 961 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.

3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

Remarks:

	/s/ Lorin Wagner, Attorney-In-Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)